menu

CME: Advances in Immuno-Oncology: Evaluating a Bispecific, Bifunctional Fusion Protein

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Advances in Immuno-Oncology: Evaluating a Bispecific, Bifunctional Fusion Protein

Advances in Immuno-Oncology: Evaluating a Bispecific, Bifunctional Fusion Protein
RestartResume
Learn more about the role of TGF-β in the pathophysiology of tumor cells and how this pathway can potentially lead to breakthrough therapies.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    About 20% of patients treated with anti-PD-1/PD-L1 checkpoint inhibitors respond to therapy. At issue is the existence and action of immunosuppressive cytokine transforming growth factor-beta (TGF-β) in the tumor microenvironment, which inhibits the normal anti-tumor action of natural killer cells and T cells. TGF-β is involved in many other processes of cancer progression and metastasis such as fibroid cap formation, epithelial-to-mesenchymal transition, and angiogenesis.

    This activity will explore new horizons in immune checkpoint inhibition with bispecific bifunctional fusion molecules that pharmacologically target the PD-L1 immunosuppression pathway and serve as a TGFβ trap. Clinicians will gain insights into the rationale for development of such a molecule and its mechanisms of action, and explore preliminary clinical experience in a variety of solid tumor types to improve patient outcomes.

    For more episodes in this series, visit ReachMD.com/IO.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    James L. Gulley, MD, PhD, FACP
    Chief, Genitourinary Malignancies Branch
    Head, Immunotherapy Group, GMB
    Director, Medical Oncology Service
    Center for Cancer Research, NCI, NIH
    Bethesda, MD

    Dr. Gulley has nothing to disclose.

    Host:
    Barnett Mennen, MD
    Physician, Capital HealthCare, PC
    Bethesda, MD

    Dr. Mennen has nothing to disclose. 

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the rationale for using bispecific, bifunctional fusion protein molecules as a treatment modality for patients with a range of cancer types.
    • Summarize the critical relationships between PD-L1 and TGF-β in regulating tumor growth and metastasis, forming the rationale for bispecific, bifunctional fusion protein molecules that contain “biologic traps,” as one part of immuno-oncologic efforts to harness the immune system when treating a range of cancer types.
    • Discuss data from early phase clinical trials providing proof of concept for M7824 as a treatment modality for patients with cancer.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, hematologists, and medical oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent medical education grant provided by Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients with cancer. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”.  

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.